Sensus Healthcare (SRTS) to Release Quarterly Earnings on Wednesday

Sensus Healthcare (NASDAQ:SRTS) is expected to be issuing its quarterly earnings data after the market closes on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $10.31 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Sensus Healthcare Trading Down 1.5 %

Shares of SRTS stock opened at $8.11 on Tuesday. Sensus Healthcare has a 1 year low of $2.91 and a 1 year high of $9.33. The firm’s fifty day simple moving average is $7.50 and its 200 day simple moving average is $6.84. The firm has a market capitalization of $132.91 million, a P/E ratio of 14.23 and a beta of 1.21.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SRTS shares. Lake Street Capital assumed coverage on shares of Sensus Healthcare in a research report on Friday. They set a “buy” rating and a $18.00 price objective for the company. HC Wainwright upped their price target on Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, November 18th. Finally, Maxim Group lifted their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, November 15th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.